| [1] |
Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci USA,1986,83:8819 -8823.
|
| [2] |
Mazzali M, Kipari T, Ophascharoensuk V, et al. Osteopontin:a molecule for all seasons. Q J M,2002,95:3 -13.
|
| [3] |
Christensen B, Nielsen M S, Haselmann K F, et al. Posttranslationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five Oglycosylation sites and their biological implications. Biochem J,2005,390:285 -292.
|
| [4] |
Christensen B, Petersen T E, S rensen E S. Post-translational modification and proteolytic processing of urinary osteopontin.Biochem J,2008,411:53 -61.
|
| [5] |
Giancotti F G,Ruoslahti E. Integrin signaling. Science,1999,285:1028 -1032.
|
| [6] |
Furger K A, Allan A L, Wilson S M, et al. Beta(3) integrin expression increases breast carcinoma cell responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer Res,2003,1:810 -819.
|
| [7] |
Katagiri Y U,Sleeman J,Fujii H,et al. CD44 variants but not CD44s cooperate with beta1-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res,1999,59:219 -226.
|
| [8] |
Denhardt D T, Noda M. Osteopontin expression and function:role in bone remodeling. J Cell Biochem Suppl,1998,30 -31:92 -102.
|
| [9] |
Hamada Y, Yuki K, Okazaki M, et al. Osteopontin-derived peptide SVVYGLR induces angiogenesis in vivo. Dent Mater J,2004,23:650 -655.
|
| [10] |
Ashkar S, Weber G F, Panoutsakopoulou V, et al. Eta-1(osteopontin): an early component of type-1 (cell mediated)immunity. Science,2000,287:860 -864.
|
| [11] |
Rittling S R, Novick K E. Osteopontin expression in mammary gland development and tumorigenesis. Cell Growth Differ,1997,8:1061 -1069.
|
| [12] |
Nemir M, Bhattacharyya D, Li X, et al. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem,2000,275:969 -976.
|
| [13] |
Brown L F, Berse B, Van de Water L, et al. Expression and distribution of osteopontin in human tissues: widespread association with luminal epithelial surfaces. Mol Biol Cell,1992,3:1169 -1180.
|
| [14] |
Senger D R,Perruzzi C A, Papadopoulos A,et al. Purification of a human milk protein closely similar to tumor-secreted phosphoproteins and osteopontin. Biochim Biophys Acta,1989,996:43 -48.
|
| [15] |
Nagatomo T, Ohga S, Takada H, et al. Microarray analysis of human milk cells: persistent high expression of osteopontin during the lactation period. Clin Exp Immunol, 2004,138:47 -53.
|
| [16] |
El Tanani M K, Campbell F C, Kurisetty V, et al. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev,2006,17:463 -474.
|
| [17] |
Shevde L A, Samant R S, Paik J C, et al. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin Exp Metastasis, 2006,23:123-133.
|
| [18] |
Bellahene A,Castronovo C. Increased expression of osteonectin and osteopontin, two bone matrix proteins in human breast cancer. Am J Pathol,1995,146:95 -100.
|
| [19] |
Castronovo V, Bellahcene A. Evidence that breast cancer associated microcalcifications are mineralized malignant cells.Int J Oncol,1998,12:305 -308.
|
| [20] |
Oyama T, Sano T, Hikino T, et al. Microcalcifications of breast cancer and atypical cystic lobules associated with infiltration of foam cells expressing osteopontin. Virchows Arch,2002,440:267 -273.
|
| [21] |
Tse G M, Tan P H, Cheung H S, et al. Intermediate to highly suspicious calcification in breast lesions: a radio-pathologic correlation. Breast Cancer Res Treat,2007,110:1 -7.
|
| [22] |
Tuck A B, O'Malley F P, Singhal H, et al. Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. Arch Pathol Lab Med,1997,121:578 -584.
|
| [23] |
Kreunin P, Urquidi V, Lubman D M, et al. Identification of metastasis-associated proteins in a human tumor metastasis model using the mass-mapping technique. Proteomics,2004,4:2754 -2765.
|
| [24] |
Suzuki M, Mose E, Galloy C, et al. Osteopontin gene expression determines spontaneous metastatic performance of orthotopic human breast cancer xenografts. Am J Pathol,2007,171:682 -692.
|
| [25] |
Hullinger T G,Taichman R S,Linseman D A,et al. Secretory products from PC-3 and MCF-7 tumor cell lines upregulate osteopontin in MC3T3-E1 cells. J Cell Biochem, 2000,78:607 -616.
|
| [26] |
Schneider D, Liaw L, Daniel C, et al. Inhibition of breast cancer cell adhesion and bone metastasis by the extracellular adherence protein of Staphylococcus aureus. Biochem Biophys Res Commun,2007,357:282 -288.
|
| [27] |
Tuck A B, Arsenault D M, O'Malley F P. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene,1999,18:4237-4246.
|
| [28] |
Fisher J L, Field C L, Zhou H, et al. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases-a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases. Breast Cancer Res Treat,2000,61:1 -12.
|
| [29] |
Das R, Mahabeleshwar G H, Kundu G C. Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem,2003,278:28 593 -28 606.
|
| [30] |
Das R, Philip S, Mahabeleshwar G H, et al. Osteopontin: it's role in regulation of cell motility and nuclear factor kappa Bmediated urokinase type plasminogen activator expression.IUBMB Life,2005,57:441 -447.
|
| [31] |
Das R, Mahabeleshwar G H, Kundu G C. Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem,2004,279:11051 -11064.
|
| [32] |
Tuck A B, Hota C, Wilson S M, et al. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.Oncogene,2003,22:1198 -1205.
|
| [33] |
El Tanani M, Platt Higgins A, Rudland P S, et al. Ets gene PEA3 cooperates with beta-catenin-Lef-1 and c-Jun in regulation of osteopontin transcription. J Biol Chem,2004,279:20 794 -20 806.
|
| [34] |
Mi Z, Guo H, Wai P Y, et al. Differential osteopontin expression in phenotypically distinct subclones of murine breast cancer cells mediates metastatic behavior. J Biol Chem,2004,279:46 659 -46 667.
|
| [35] |
Adwan H, Bauerle T J, Berger M R. Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells. Cancer Gene Ther2004,11:109 -120.
|
| [36] |
Costa C, Soares R, Schmitt F. Angiogenesis: now and then.Acta Pathol Microbiol Immunol Scand,2004,112:402 -412.
|
| [37] |
Soares R, Reis Filho J, Gartner F, et al. VEGF, TGFα and estrogen receptors: possible crosstalks and interactions. Am J Pathol,2002,160:381 -382.
|
| [38] |
Soares R, Guo S, Russo J, et al. Role of the estrogen antagonist ICI 182 780 in vessel assembly and apoptosis of endothelial cells. Ultrastruct Pathol,2003,27:33 -39.
|
| [39] |
Soares R, Balogh G, Guo S, et al. Evidence for the notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol,2004,18:2333 -2343.
|
| [40] |
Brooks P Cc, Clark R A, Cheresh D A. Requirement of vascular integrin Ctvrl3 for angiogenesis. Science,1994,264:569 -571.
|
| [41] |
Brooks P Cc, Montgomery A M, Rosenfeld M, et al. Integrin ανβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994,79:1157 -1164.
|
| [42] |
Liaw L, Lindner V, Schwartz S M, et al. Osteopontin and β3 integrin are coordinately expressed in regenerating endothelium in vivo and stimulate Arg-Gly-Asp-dependent endothelial migration in vitro. Circ Res,1995,77:665 -672.
|
| [43] |
Senger D R, Ledbetter S R, Claffey K P, et al. Stimulation of endothelial cell migration by vascular permeability factor/vascular endothelial growth factor through cooperative mechanisms involving the ανβ3 integrin, osteopontin, and thrombin. Am J Pathol,1996,149:293 -305.
|
| [44] |
Malyankar U M, Scatena M, Suchland K L, et al.Osteoprotegerin is an ανβ3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem, 2000,275:20 959 -20 962.
|
| [45] |
Chakraborty G, Jain S, Kundu G C. Osteopontin promotes vascular endothelial growth factor-dependent breast tumor growth and angiogenesis via autocrine and paracrine mechanisms. Cancer Res,2008,68:152 -161.
|
| [46] |
Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxelinduced apoptosis in breast cancer cells. Oncogene,2001,20:4995 -5004.
|
| [47] |
Zhang Z, Vuori K,Reed J C,et al. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression. Proc Natl Acad Sci USA,1995,92:6161-6165.
|
| [48] |
Damiano J S, Cress A E, Hazlehurst L A, et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood,1999,93:1658 -1667.
|
| [49] |
Graessmann M, Berg B, Fuchs B, et al. Chemotherapy resistance of mouse WAP-SVT/t breast cancer cells is mediated by osteopontin, inhibiting apoptosis downstream of caspase-3.Oncogene,2007,26:2840 -2850.
|
| [50] |
Rudland P S, Platt Higgins A, El Tanani M, et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res,2002,62:3417 -3427.
|
| [51] |
Patani N, Jiang W, Mokbel K. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. Int J Cancer,2008,122:2646.
|
| [52] |
Senger D R, Perruzzi C A, Gracey C F, et al. Secreted phosphoproteins associated with neoplastic transformation:close homology with plasma proteins cleaved during blood coagulation. Cancer Res,1988,48:5770 -5774.
|
| [53] |
Brown L F, Papadopoulos Sergiou A, Berse B, et al.Osteopontin expression and distribution in human carcinomas.Am J Pathol,1994,145:610 -623.
|
| [54] |
Bautista D S, Saad Z, Chambers A F, et al. Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and post-menopausal women. Clin Biochem, 1996,29:231 -239.
|
| [55] |
Singhal H, Bautista D S, Tonkin K S, et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res,1997,3:605 -611.
|
| [56] |
Bramwell V H, Doig G S, Tuck A B, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res,2006,12:3337 -3343.
|
| [57] |
Plumer A, Duan H, Subramaniam S, et al. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer. BMC Cancer,2008,8:38 -48.
|